Join our presentation on June 29 to explore the latest technologies and developments in evaluating microbiota composition related to health and disease in the small intestine. Our expert Els van Hoffen will inform you about our microbiota analyses performed on samples collected in the small intestine. Interested in a meeting? Contact us in advance. We hope to see you there!
The role played by microbes in an array of infectious diseases has been known for over a hundred years. With recent contributions from large scale initiatives including the NIH Human Microbiome Project, significant technological advances in sequencing methodology and privately funded backing, the human microbiome has become a realistic therapeutic intervention in treating disease.
Despite a unified goal of creating safe, effective and commercially-viable therapeutics that directly impact the microbiome in treating disease, there are currently a diverse array of approaches adopted by industry to achieve this.
Being part of Microbiome Drug Development Summit gives you the opportunity to get unprecedented access to the latest preclinical, clinical and commercial case studies from the brightest minds in biopharma and academia to turn microbiome discoveries of today into patient therapies of the future.